Artemether‐Lumefantrine versus Dihydroartemisinin‐Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children

Abstract

Artemether-lumefantrine and dihydroartemisinin-piperaquine were both efficacious and had similar long-term effects on the risk of recurrent malaria. Clinical trials registration. NCT00527800.

Accuracy of Two Malaria Rapid Diagnostic Tests (RDTS) for Initial Diagnosis and Treatment Monitoring in a High Transmission Setting in Uganda

“…Details of the screening and recruitment of this cohort have been published previously. 17 Briefly, children were recruited from the antenatal and pediatric clinics of Tororo Hospital and Tororo branch of The AIDS Support Organization (TASO) if they fulfilled all of the following eligibility criteria: 1) age 6 weeks to 12 months, 2) documented HIV status of mother and child, 3) agreement to come to the study clinic for any febrile episode or other illness, 4) agreement to avoid medications administered outside the study protocol, 5) willingness of parents or guardians to provide informed consent, and 6) residence within 30 km radius of the study clinic. Children in the study cohort were seen at least monthly at the study clinic and encouraged to attend the clinic in case of any illness and to avoid any medication not given at the study *Address correspondence to Phoebe Mbabazi, International Hospital Kampala, P.O.…”

Increased Risk of Early Vomiting among Infants and Young Children Treated with Dihydroartemisinin-Piperaquine Compared with Artemether-Lumefantrine for Uncomplicated Malaria

“…2 Dihydroartemisinin-piperaquine (DP) is emerging as a favorable antimalarial option with comparable clinical efficacy to AL, prolonged post-treatment prophylaxis, and a simple once a day dosage regimen. [3][4][5][6] The ACTs appear to be well-tolerated and serious toxicities are rare. 1,4,5,7 Early vomiting (vomiting within one hour of dosing) has been reported in 3% of courses of AL 4 and DP 4,6 in adults.…”

“…[10][11][12] Details of the primary study have been reported. 3 As part of a pharmacokinetic substudy, detailed data on drug administration and early vomiting were recorded for all new cases of uncomplicated malaria that occurred during May 31-November 7, 2008.…”

Comparing the Impact of Artemisinin-Based Combination Therapies on Malaria Transmission in Sub-Saharan Africa

“…8 A variety of ACTs exists, such as artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP), which vary in their efficacy profile against uncomplicated malaria, tolerability, and their ability to reduce infectivity to mosquitoes. 8,[11][12][13][14] The difference in efficacy between these ACTs may have important implications not only for the treatment of individual patients, but also for the population-level impact on malaria transmission. 11,13 The balance among these factors, which may themselves vary between communities, will determine whether AL or DP is optimal in different settings.…”

“…The AL remains the most widely used ACT in Africa. 8,12 However, DP, a newer ACT, may appear equally efficacious as AL but with simpler dosing and a longer prophylactic period because of the extended half-life of piperaquine. 8,15,16 Comparative efficacy studies in multiple settings have consistently reported a longer duration to recurrent infection in individuals treated with DP as compared with AL.…”